Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Thymoma × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 50 Cholangiocarcinoma 18 Carcinoma, Renal Cell 12 Biliary Tract Neoplasms 8 Thyroid Neoplasms 6 Stomach Neoplasms 6 Neoplasms 6 Endometrial Neoplasms 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Uterine Cervical Neoplasms 4 Recurrence 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Thyroid Carcinoma, Anaplastic 3 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Liver Neoplasms 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Advanced Biliary Tract Cancer 3 Vulvar Neoplasms 2 Uveal Melanoma 2 Thyroid Cancer, Papillary 2 Solid Tumors 2 Neuroendocrine Tumors 2 Mesothelioma, Malignant 2 Gallbladder Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Adenoid Cystic 2

Interventions

Sunitinib 4 Paclitaxel 4 Carboplatin 4 pembrolizumab 3 Cyclophosphamide 3 Cisplatin 3 selinexor 2 Taxes 2 Ramucirumab 2 Octreotide 2 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2 Erlotinib Hydrochloride 2 Chemoradiotherapy 2 zimberelimab 1 regorafenib 1 lenvatinib 1 epacadostat 1 belinostat 1 avelumab 1 atezolizumab 1 amrubicin 1 TP protocol 1 Radiotherapy 1 Radiofrequency Ablation 1 Radiation Dose Hypofractionation 1 Prednisone 1 Pemetrexed 1 Methylprednisolone 1 Melphalan 1 MK 2206 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05832827 2023-10-23

Artemis

National Cancer Center, Japan

Phase 2 Recruiting

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡